Quick Product Info At A Glance
Background of the development
Paclitaxel belongs to TAXOL group of Anti-cancer drugs. It is poorly absorbed if given through oral route as it is a p-glycoprotein inhibitor and this limits its use only to an injectable drug.
The injectable Paclitaxel is presently available as a formulation in a Polyoxyl 35 castor oil + alcohol vehicle which is a trigger for Anaphylactic reactions in the patients.
Both poor oral absorption of Paclitaxel molecule and parenteral toxicity of Paclitaxel injection suggest the need of a high bioavailable oral formulation.
A bioequivalent oral formulation in contrast to the existing Paclitaxel Injection would solve both the issues; poor absorption and anaphylactic reactions.
Our ORAL PACLITAXEL PREPARATION is water soluble, non-toxic to G.I. tract and stable at room temperature. It can be easily administered orally after dissolving in drinking water.
The injectable Paclitaxel is presently available as a formulation in a Polyoxyl 35 castor oil + alcohol vehicle which is a trigger for Anaphylactic reactions in the patients.
Both poor oral absorption of Paclitaxel molecule and parenteral toxicity of Paclitaxel injection suggest the need of a high bioavailable oral formulation.
A bioequivalent oral formulation in contrast to the existing Paclitaxel Injection would solve both the issues; poor absorption and anaphylactic reactions.
Our ORAL PACLITAXEL PREPARATION is water soluble, non-toxic to G.I. tract and stable at room temperature. It can be easily administered orally after dissolving in drinking water.
Presentation
Paclitaxel for Oral Solution Powder in a Sachet
Status
Soon entering clinical trials